LEXEO Programs

Comprehensive pipeline includes investigational AAV-mediated gene therapies in genetic cardiovascular conditions and genetic conditions of the central nervous system (CNS).

INDICATION

PROGRAMS

CNS DISORDERS

LX1004

LX1001

LX1020

LX1021

R154S "Christchurch" Alzheimer's

APOE4 Alzheimer's

APOE4- / APOE2+ Alzheimer's

CARDIAC DISORDERS

13 Undisclosed Programs

Various

LX2006

LX2020

LX2021

LX2022

Cardiac Friedreich's Ataxia

ARVC PKP2

ARVC CX43

TNNI3 HCM

CLN2 Batten

CLN2

Phase II/III

Discovery

Preclinical

Phase I/II

APOE4-/APOE2+

APOE4

Christchurch

FA

ARVC PKP2

ARVC CX43

TNNI3 HCM